Skip to content
Clinical Trials – home
AustriaBack to Austria

Clinical trials in Korneuburg – page 17

860 clinical trials in Korneuburg, Austria across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Korneuburg at a glance
860
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

860 trials in Korneuburg

Open in trial search

Study on the Effectiveness and Safety of Sonrotoclax and Zanubrutinib for Adults with Relapsed or Refractory Mantle Cell Lymphoma

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Sonrotoclax
  • Sponsor:BeOne Medicines AG

Study on Ivosidenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed IDH1-Mutated Acute Myeloid Leukemia Ineligible for Intensive Chemotherapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study Comparing BMS-986393 CAR T Cell Therapy to Standard Treatments for Adults with Relapsed or Refractory Multiple Myeloma Resistant to Lenalidomide

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Carfilzomib
  • Sponsor:Celgene Corp.

Study on the Safety and Effects of NSC001 and Trospium Chloride for Patients with Mild to Moderate Alzheimer's Disease

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:NGX-267
  • Sponsor:Nsc Therapeutics GmbH

Study on the Safety and Effectiveness of CRN04894 for Patients with Congenital Adrenal Hyperplasia

InvestigationalNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Atumelnant
  • Sponsor:Crinetics Pharmaceuticals Inc.

Study of Sacituzumab Tirumotecan and Bevacizumab for Patients with Recurrent Ovarian Cancer

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Study on Venetoclax, Obinutuzumab, and Pirtobrutinib for Patients with Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Obinutuzumab
  • Sponsor:University Of Cologne

Study on Preventing Atrial Fibrillation After Heart Surgery Using Landiolol Hydrochloride in Patients with Normal Heart Function

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Landiolol Hydrochloride
  • Sponsor:Medical University Of Vienna

Study on Treating Neovascular Age-Related Macular Degeneration with Aflibercept, Ranibizumab, and Brolucizumab for Patients with Active Disease

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Aflibercept
  • Sponsor:Medical University Of Vienna

Study on Revumenib, Azacitidine, and Venetoclax for Adults with Newly Diagnosed Acute Myeloid Leukemia Not Eligible for Intensive Chemotherapy

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Study of Pozelimab and Cemdisiran for Adults with Geographic Atrophy from Age-Related Macular Degeneration

Investigational
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Cemdisiran
  • Sponsor:Regeneron Pharmaceuticals Inc.

Study on the Safety of Edoxaban for Patients with Porto-Sinusoidal Vascular Disorder

Registered drug
Countries:AustriaAustria
  • Participants:18–64 years · 65+ years
  • Substances:Edoxaban
  • Sponsor:Medical University Of Vienna

Other cities in Austria

The busiest research cities in the country

All 48 cities in Austria
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.